Ruxolitinib + Pembrolizumab for Lymphoma

Overseen By Seda Tolu, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Seda S. Tolu

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Compensation: Varies

Number of Visits: Unknown

53 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

Who Is on the Research Team?

Seda Tolu, MD

Principal Investigator

Columbia University

Are You a Good Fit for This Trial?

This trial is for individuals with various types of lymphoma, including Mixed-Cell, Peripheral T-Cell, Hodgkin's, Cutaneous T-Cell, Non-Hodgkin's and Large B-Cell Lymphoma. Participants should have relapsed or refractory conditions after previous treatments.

Inclusion Criteria

I am 18 years old or older.

My cancer can be measured by tests.

I haven't had chemotherapy or immunotherapy in the last 2 weeks and have recovered from any side effects.

Exclusion Criteria

I do not have active tuberculosis.

Severe hypersensitivity to pembrolizumab and/or ruxolitinib

I cannot swallow or take medications orally.

What Are the Treatments Tested in This Trial?

Interventions

• Pembrolizumab
• Ruxolitinib

Trial Overview

The study is testing the combination of two drugs: Ruxolitinib and Pembrolizumab to see if they're safe and effective when used together in patients with different kinds of lymphomas that haven't responded well to other treatments.

How Is the Trial Designed?

Group I: Ruxolitinib Experimental Treatment 2 Interventions

Ruxolitinib 20mg PO twice daily will be continued until 12 months, disease progression, or development of intolerable side effects (whichever occurs first).

Who Is Running the Clinical Trial?

Seda S. Tolu

Lead Sponsor

Incyte Corporation

Industry Sponsor

Trials

408

Recruited

66,800+

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School